surmount-1 tirzepatide trial obesity without diabetes for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURMOUNT-3: Tirzepatide shows total mean
Description
Among these adipokines, adiponectin stands out as one with multiple beneficial effects on insulin sensitivity and cardiovascular well-being

More recently, the GLP-1 receptor agonist semaglutide 2.4 mg weekly dose was approved for the management of obesity in the USA in 2021 and in Australia in 2024

GLP-1R activation can induce proximal tubular natriuresis via inhibition of sodium/hydrogen exchanger isoform 3
This works with the slowed gastric emptying rather than against it

I wont lie, it was a little painful, but totally worth it
